The bicyclam CXCR4 antagonist plerixafor (known in the literature as AMD3100) was originally developed to inhibit cell entry of HIV X4-strains via CXCR4; however, initial in vivo preclinical tests revealed a massive leukocytosis following plerixafor administration15. This evidence concerns the gene CXCR4 and Increased total leukocyte count.